StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.25+0.14 (+0.87%)

Close on Nov 18, 2026Market cap $3.01BP/E –Yield –

Legend Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Legend Biotech's operating income for the twelve months ending Jun 30, 2026 was -$55.18M. For fiscal 2025 it was -$136.50M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$136.50M–
FY2024Dec 31, 2024-$309.50M–
FY2023Dec 31, 2023-$528.10M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.70M–
Q1 FY2026Mar 31, 2026-$49.80M–
Q4 FY2025Dec 31, 2025-$19.63M–
Q3 FY2025Sep 30, 2025-$43.45M–
Q2 FY2025Jun 30, 2025-$21.90M–
Q1 FY2025Mar 31, 2025-$51.70M–
Q4 FY2024Dec 31, 2024-$79.31M–
Q3 FY2024Sep 30, 2024-$70.36M–

More Legend Biotech figures

See a number that looks wrong?